Average weight loss per week on Mounjaro: what the trial data shows

Where the 0.4–0.5 kg per week figure comes from

The most cited weekly figure derives from the SURMOUNT-1 trial published in the New England Journal of Medicine, the largest placebo-controlled study of tirzepatide for weight management. Over 72 weeks, participants at the 15 mg dose lost a mean of around 20–21% of their body weight. Divide that by 72 weeks and you arrive at roughly 0.4–0.5 kg per week as a straight mathematical average, but that arithmetic flattens something important.

Weight loss on Mounjaro is not linear. Loss tends to be sharpest in the first 12 to 24 weeks, when appetite suppression is most pronounced and the body is responding to each dose increase. It slows through the middle phase as body weight falls and energy expenditure adjusts, then plateaus near the end of the active treatment period. The weekly average of 0.4–0.5 kg is pulled up by those fast early weeks and pulled down by the plateau. In practice, some people lose closer to 0.8–1 kg a week in the early months and far less (or nothing at all for a stretch) later on.

For context, what tends to happen in the very first week is often modest, because 2.5 mg is a dose designed to let the body adjust, not to produce immediate scale movement. Understanding that distinction from the start can spare a lot of unnecessary anxiety.

Why dose level shapes your weekly rate more than almost anything else

Tirzepatide's titration schedule runs from 2.5 mg up through 5, 7.5, 10, 12.5 and 15 mg, typically increasing every four weeks under a prescriber's direction. Each step up tends to bring a fresh wave of appetite reduction, and the trial data consistently shows that higher maintenance doses produce greater total and weekly loss. The difference between 5 mg and 15 mg in SURMOUNT-1 was clinically meaningful: mean weight reduction at 5 mg was around 15%, compared with 20–21% at 15 mg over the same 72 weeks.

This is why comparing your weekly loss with someone else's at a different dose stage rarely tells you much. Someone three months into treatment at 7.5 mg and someone 18 months in at 15 mg are on very different trajectories. Average weight loss figures for tirzepatide across dose levels give a more granular picture of what to expect at each stage.

It's also worth knowing that the NICE guidance on tirzepatide (detailed in NICE technology appraisal TA1026) includes a review point at six months: if someone has not achieved at least 5% weight loss at their highest tolerated dose by then, continuing treatment is reviewed. That benchmark anchors what the clinical bar looks like, independent of the weekly average.

What slows the weekly rate, and when a plateau is normal

A flattening of the weekly loss curve is expected, not a sign something has gone wrong. Several things contribute: as body mass falls, total daily energy expenditure falls with it; the body mounts an adaptive response that partially offsets the calorie deficit; and the appetite-suppressing effect, while maintained, operates against a smaller target weight. The result is that the same dose produces less scale movement in month 12 than in month three.

Separately, some people notice stretches where loss stalls entirely. Stalling on Mounjaro is a common question our prescribers hear, usually prompted by a run of weeks without movement on the scales despite adherence. Causes range from fluid retention and hormonal cycles to simple measurement noise. A genuine plateau lasting several weeks at a sub-maximum dose is often a prompt to discuss titration with your prescriber.

Lifestyle factors carry real weight here too. Protein intake, resistance exercise, sleep quality and hydration all interact with the medicine's mechanism. No one variable overrides another completely, but the trial participants who did best tended to combine tirzepatide with meaningful dietary and activity changes, and what happens in the first month often sets the tone for those habits.

Putting weekly averages into practical perspective

The 0.4–0.5 kg per week figure is best read as a benchmark for the programme as a whole, not a target to hit each Sunday morning. Most people's scales don't move like clockwork; weigh-ins can swing by a kilogram between morning and evening depending on hydration alone. Weekly tracking, averaged over two to four weeks, gives a more honest picture than day-to-day readings.

One practical note: people who start treatment mid-month sometimes find the timing question pops up, whether it's worth starting before a holiday, after a bank holiday, or lined up with a payday order. The clinical answer is that the best time to start is when you can manage consistent weekly injections and the early GI adjustment that often comes with them. Rushing the start date for calendar reasons rarely helps.

If you want to understand how your own profile (your starting BMI, any relevant health conditions, your dose history) fits against these averages, how long Mounjaro typically takes to produce visible results answers the timeline question in more depth. And for a full picture of what Mounjaro is, how it works and who it's licensed for, our main overview covers all of it. To explore private treatment through a GPhC-registered pharmacy with same-day clinical review, speak to our prescribers, the consultation is free.